St. Jude Medical Reports First Quarter 2016 Results

Go back to St. Jude Medical Reports First Quarter 2016 Results

Needham & Company Raises Price Target on St. Jude Medical (STJ) Following Strong 1Q Results

April 20, 2016 1:14 PM EDT

Needham & Company reiterated a Strong Buy rating on St. Jude Medical (NYSE: STJ), and raised the price target to $75.00 (from $70.00), following the company's 1Q earnings report. STJ reported revenue of $1.448B, ahead of the consensus estimate of $1.436B. EPS was reported at $0.90 compared to consensus of $0.88.... More

St. Jude Medical (STJ) Tops Q1 EPS by 2c

April 20, 2016 7:16 AM EDT

St. Jude Medical (NYSE: STJ) reported Q1 EPS of $0.90, $0.02 better than the analyst estimate of $0.88. Revenue for the quarter came in at $1.45 billion versus the consensus estimate of $1.43 billion.

GUIDANCE:

St. Jude Medical sees Q2 2016 EPS of $1.05-$1.07, versus the... More